

“A direct, efficient method for the preparation of siRNAs containing ribo-like North bicyclo[3.1.0]hexane pseudosugars” Terrazas, M., Aviñó, A., Siddiqui, M., Marquez, V., Eritja, R. *Org. Lett.*, 13(11), 2888-2891 (2011).
PMID: 21553811, doi: 10.1021/ol200909j


A direct, efficient method for the preparation of siRNAs containing ribo-like North bicyclo[3.1.0]hexane pseudosugars

Montserrat Terrazas,[†] Anna Aviñó,[†] Maqbool A. Siddiqui,[‡]
Victor E. Marquez,^{*,‡} and Ramon Eritja^{*,†}

Institute for Research in Biomedicine (IRB Barcelona), Networking Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), and Institute for Advanced Chemistry of Catalonia (IQAC), Spanish Research Council (CSIC), Cluster Building, Baldori i Reixac 10, E-08028 Barcelona, Spain, and Laboratory of Chemical Biology, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD 21702 USA.

Email Address: recgma@cid.csic.es

Abstract:



An efficient method for the preparation of siRNAs modified with ribo-like North bicyclo[3.1.0]hexane pseudosugars is described. The combined use of 2'-O-(2-cyanoethoxymethyl) (CEM) and 2'-O-TBDMS protection was successfully employed for RNA synthesis with the added advantage that both groups were efficiently removed in a single step. The resulting North ribo-methanocarpa-modified siRNAs are compatible with the intracellular RNAi machinery and can mediate specific degradation of target mRNA.

Nucleotide analogues that exhibit the North-type sugar pucker¹ and possess the overall A-RNA-type conformation have attracted much interest in the field of RNA interference (RNAi) therapy.² RNAi is a sequence-specific RNA silencing mechanism³ triggered by double-stranded RNA or short interfering RNA molecules (siRNA), which are formed by a sense and a guide strand.⁴ Within the cells, an RNA-induced silencing complex (RISC)⁵ unwinds the siRNA duplex and uses the guide strand as a template to find the complementary target mRNA,⁶ an event that induces the endonucleolytic cleavage of the mRNA⁷ and prevents its translation into protein. For efficient gene silencing to take place, the guide siRNA:mRNA duplex must adopt an A-type helical structure.⁸ In order to fulfill these requirements and to improve target-binding affinity, several North-locked nucleotide building blocks have been designed, synthesized, and

incorporated into siRNAs.⁹ Examples are 2'-O-alkylated RNAs,^{8b,10} 2'-fluoro-RNAs,^{8b,10a,11} and Locked Nucleic Acids (LNA); the latter containing a methylene bridge between the 2' oxygen and the 4' carbon.¹² In particular, LNAs have been widely explored and it is well known that LNA-modified siRNAs efficiently induce the RNAi process and increase the thermodynamic and serum stability of RNA duplexes to a great extent.¹³

Another candidate for introducing new features into siRNAs without perturbing the A-type helical structure they require for activity is the North-locked form of nucleotide analogues based on a carbocyclic bicyclo[3.1.0]hexane system [methanocarpa (MC) nucleosides]. Preliminary studies on the effect of North 2'-deoxy-MC nucleosides on the RNAi process have shown that these pseudonucleosides are accepted by the RNAi machinery.¹⁴ However, the effect of a hydroxyl group at the 2' position of any of the modified sugars, or the carbocyclic pseudosugar, on the RNAi process has never been investigated. The design and synthesis of North ribo-MC nucleosides (Figure 1) has been reported.¹⁵ Nevertheless, these derivatives have never been incorporated into RNA strands.




Figure 1. North ribo-methanocarpa cytidine monomer (CN)

Herein we describe a synthetic strategy for the preparation of conveniently 2'-O-protected phosphoramidite of North ribo-MC cytidine (CN) (Figure 1). We also describe its incorporation into mixed 2'-O-protected RNA strands and the removal of the 2'-O-protecting groups of the RNAs in a single step. This approach permits an easy access to the preparation of North ribo-MC cytidine-modified siRNAs with potential therapeutic applications.


An important challenge in the preparation of RNA strands modified with North ribo-MC is the protection of the 2'-OH group of the pseudoribose. Preliminary studies on the reactivity of the 2'-OH group of North ribo-MC cytidine carried out in our group have shown that the 3'-OH is much more reactive than the 2'-OH group (data not shown). Thus, in contrast to what has been reported for a great number of nucleoside derivatives,¹⁶ the direct protection of the 2'-OH group of 5'-O-protected ribo-MC cytidine derivatives with a free 3'-hydroxyl group becomes a serious problem. The attempted strategy was to employ a 3',5'-O-disiloxan diprotected intermediate with a free 2'-OH group (1, Scheme 1). Our first try involved the protection of the free 2'-OH in 1 with a benzoyl group. However, this route was abandoned due to the rapid migration of the 2'-O-benzoyl from the 2'-OH to the 3'-OH after deprotection.

A wide variety of 2'-O-protecting groups have been developed for RNA synthesis.^{16,17} For example, fluoride-labile protecting groups such as tert-butyldimethylsilyl (TBDMS),^{17a} [(triisopropylsilyl)oxy]methyl (TOM)^{17b} and 2-cyanoethoxymethyl (CEM)^{17c} groups, or the photo-labile [(2-nitrobenzyl)oxy]methyl group^{17d} among others.¹⁶ TBDMS and TOM are popular 2'-OH protecting groups whose phosphoramidites are commercially available. We decided to use the cheaper 2'-O-TBDMS-protected phosphoramidites of natural ribonucleosides for RNA synthesis.

However, for the protection of the 2'-OH group of the 3',5'-O-disiloxan protected MC nucleoside 1, the fluoride-labile TBDMS and TOM groups had to be avoided since the disiloxane protecting group is also removed by a fluoride reagent like TBAF. To overcome these problems, the group of Wada et al. have found a way to prevent the removal of the CEM group during the removal of the disiloxan group of 3',5'-O-disiloxan-2'-O-CEM-protected nucleosides, by treatment with TBAF in the presence of AcOH.¹⁸

As for RNA synthesis, removal of the CEM group from fully 2'-O-CEM-protected RNA strands has been successfully achieved under aprotic conditions.¹⁹ In our search for a synthetic method that would allow ready cleavage of the 2'-O-protecting group of the MC nucleoside and the 2'-O-TBDMS protecting group of natural nucleosides from the final RNA product in only one step, we decided to focus on the CEM group.

Scheme 1. Preparation of 2'-O-CEM-protected ribo-MC cytidine building block



The synthesis of compound 1 is relatively straightforward and it is described in the supplementary section. As described in Scheme 1, compound 1 was treated with 2-cyanoethyl methylthiomethyl ether to give the desired 2'-O-CEM-3',5'-O-disiloxan-protected derivative 2 in 73% yield. Following the fluoride-catalyzed removal of the disiloxan protecting group the desired 2'-O-CEM protected diol 3 was obtained in 90% yield. The 5' hydroxyl group was then protected by a 4,4'-dimethoxytrityl group (DMT) and the resulting 5'-O-DMT-2'-O-CEM-protected nucleoside 4 was converted into the desired phosphoramidite (5).

With compound 5 at hand we proceeded to incorporate this nucleotide building block (CN) into different positions in place of the natural ribocytidine along a 21-mer RNA guide strand that targets the Renilla luciferase mRNA by using a DNA/RNA synthesizer. The solid-phase synthesis was carried out on a 0.2 μ mol scale with a coupling time of 10 min. For CN-modified RNAs, P(III) to P(V) oxidation was performed with a solution of 10% tert-butyl hydroperoxide in acetonitrile/water (96:4). Commercially available succinyl polystyrene functionalized with 5'-O-DMT-2'-deoxythymidine was used as the solid support and tetrazole as the activator.

Phosphoramidites of 2'-O-TBDMS protected natural ribonucleosides (A, U, G and C) were obtained from commercial sources. We prepared RNA guide strands containing no substitutions (6, wt), one CN substitution at position 8 (7) and two CN substitutions spaced-out along the guide strand at positions 8 and 15 (8). We also prepared the corresponding unmodified sense strand (Table 1).

After RNA synthesis, the DMT-on polystyrene solid support was treated with a mixture of 33% ammonia solution and ethanol [3:1 (v/v)] for 24 h at 35 °C for the cleavage from the polystyrene solid support and the removal of the phosphate-protecting and base-protecting groups. In the next step, the 2'-O-TBDMS protecting group of unmodified guide (6) and sense strands was completely removed by treatment with 1 M TBAF/THF for 12 h.

Table 1. Sequences of RNAs and T_m data

1	3'-TTAAAAAGAGGAAGAAGUCUA (sense)	
2	5'-UUUUUCUCCUUCUUCAGAUTT (guide, 6, wt)	67.6
3	5'-UUUUUCUCNCUUCUUCAGAUTT (guide, 7)	65.9
4	5'-UUUUUCUCNCUUCUUCNAGAUTT (guide, 8)	64.5

T_ms were measured in 15 mM HEPES-KOH (pH 7.4), 1 mM MgCl₂ and 50 mM KOAc.

For the removal of 2'-O-TBDMS and 2'-O-CEM protecting groups of RNAs 7 and 8, 10% n-propylamine and 1% of bis(2-mercaptoethyl) ether in 1M TBAF/THF was used instead of 1 M TBAF/THF to prevent formation of CEM adducts, a side reaction reported by Ohgi et al.¹⁴ These authors report complete removal of 2'-O-CEM protecting groups of fully 2'-O-CEM protected RNA strands after 6 h at r.t. Under these conditions, we obtained mixtures of 2'-O-protected and 2'-O-deprotected RNAs (as evaluated by HPLC). We increased the reaction time (to 12, 15 and 24 h) and after shaking at room temperature for 24 h, HPLC analysis of the crude oligo showed a single main peak corresponding to the fully deprotected product and only small amounts of shorter products (Figure 2A). Fully 2'-O-deprotected RNAs (6, 7, 8 and sense) were purified by reverse phase semi-preparative HPLC in the DMT-on mode. Finally, the DMT-on products were treated with 80% AcOH solution to remove the DMT group and the de-protected products were desalted on NAP columns. The desired products were obtained in good overall yields (7, 58%; 22 OD; 8, 35%, 13 OD).




Figure 2. HPLC analysis of RNA 7. (A) Unpurified fully deprotected RNA 7. (B) Purified fully deprotected RNA 7.

RNA strands 7 and 8 were treated with nuclease P1 and then alkaline phosphatase, and the digestion products were analyzed by HPLC. No modified ribonucleosides (2'-O-CEM protected ribo-MC cytidine or 2'-O-TBDMS protected U, A, C and G) were observed; showing that complete removal of the CEM and TBDMS protecting groups and base-protecting groups was achieved.

Finally, in order to study the effect of the ribo North MC cytidine substitution on the RNA interference process, we carried out separate RNAi studies in SH-SY5Y cells with siRNA duplexes containing each of the modified guide strands (7 and 8), as well as with the unmodified (wt) guide RNA (6). Experiments were carried out in triplicate. The cells were first transfected with dual reporter plasmids that express Renilla luciferase (the target) and non-targeted firefly as an internal control. The effects of the different siRNAs on luciferase expression were evaluated using 26-0.03 nM siRNA concentrations in the cell media and measuring luciferase responses after 22 h. The results show that the RNAi machinery is not impaired by the North MC riboC modification (Figure S27). The best results were obtained for siRNA containing one substitution in the guide strand (7), which showed activity comparable to that of wt siRNA (6). To confirm the specificity of the observed effects, sequence-scrambled siRNAs were used (Table S1). As expected, scrambled sequences gave no Renilla inhibition (Figure S27). Thermal denaturation studies suggested that the CN modification caused a slight destabilization of the siRNA duplex ($\Delta T = -1.6$ °C per substitution; Table 1). However, such small destabilization did not significantly affect RNAi activity.

In conclusion, in this work we have reported an strategy for (i) the preparation of North ribo-MC nucleosides conveniently protected at the 2'-OH position, (ii) their incorporation into mixed 2'-O-protected RNA strands and (iii) the removal of the 2'-O-protecting groups of the RNA in only one step. To the best of our knowledge, this is the first time that the synthesis and one-step de-protection of a 2'-O-TBDMS/2'-O-CEM oligoribonucleotides has been described.

Acknowledgment. This research was supported by the Spanish Ministry of Education (BFU2007-63287 and CTQ2010-20541-C03-01) and the Generalitat de Catalunya (2009/SGR/208) and the Instituto de Salud Carlos III. This work was funded in part by the Center for Cancer Research, National Cancer Institute, NIH. M. T. Acknowledges Juan de la Cierva contract (MICINN, Spain) for financial support.

† IRB Barcelona.

‡ National Cancer Institute at Frederick.

(1) Altona, C.; Sundaralingam, M. *J. Am. Chem. Soc.* 1973, 95, 2333.

(2) (a) Manoharan, M. *Biochim. Biophys. Acta* 1999, 1489, 117. (b) Freier, S. M.; Altmann, K. H. *Nucleic Acids Res.* 1997, 25, 4429.

(3) (a) Fire, A.; Xu, S.; Montgomery, M. K.; Kostas, S. A.; Driver, S. E.; Mello, C. C. *Nature* 1998, 391, 806. (b) Elbashir, S. M.; Harborth, J.; Lendeckel, W.; Yalcin, A.; Weber, K.; Tuschl, T. *Nature* 2001, 411, 494. (c) Bumcrot, D.; Manoharan, M.; Koteliensky, V.; Sah, D. W. Y. *Nat. Chem. Biol.* 2006, 2, 711.

(4) (a) Elbashir, S. M.; Lendeckel, W.; Tuschl, T. *Genes Dev.* 2001, 15, 188. (b) Elbashir, S. M.; Martinez, J.; Patkaniowska, A.; Lendeckel, W.; Tuschl, T. *EMBO J.* 2001, 20, 6877. (c) Tang, G.; Reinhart, B. J.; Bartel, D. P.; Zamore, P. D. *Genes Dev.* 2003, 17, 49.

- (5) (a) Hammond, S. M.; Bernstein, E.; Beach, D.; Hannon, G. J. *Nature* 2000, 404, 293. (b) Valencia-Sanchez, M. A.; Liu, J.; Hannon, G.J.; Parker, R. *Genes Dev.* 2006, 20, 515.
- (6) Nykänen, A.; Haley, B.; Zamore, P. D. *Cell* 2001, 107, 309.
- (7) (a) Meister, G.; Landthaler, M.; Patkaniowska, A.; Dorsett, Y.; Teng, G.; Tuschl, T. *Mol. Cell* 2004, 15, 185. (b) Matranga, C.; Tomari, Y.; Shin, C.; Bartel, D. P.; Zamore, P. D. *Cell* 2005, 123, 607. (c) Rand, T. A.; Petersen, S.; Du, F.; Wang, X. *Cell* 2005, 123, 621.
- (8) (a) Chiu, Y.-L.; Rana, T. M. *Mol. Cell* 2002, 10, 549. (b) Chiu, Y.-L.; Rana, T. M. *RNA* 2003, 9, 1034.
- (9) For a review, see: Watts, J. K.; Deleavey, G. F.; Damha, M. J. *Drug Discov. Today* 2008, 13, 842.
- (10) (a) Dowler, T.; Bergeron, D.; Tedeschi, A.-L.; Paquet, L.; Ferrari, N.; Damha, M. J. *Nucleic Acids Res.* 2006, 34, 1669. (b) Amarzguoui, M.; Holen, T.; Babaie, E.; Prydz, H. *Nucleic Acids Res.* 2003, 31, 589. (c) Czauderna, F.; Fechtner, M.; Dames, S.; Aygün, H.; Klippel, A.; Pronk, G. J.; Giese, K.; Kaufmann, J. *Nucleic Acids Res.* 2003, 31, 2705.
- (11) Deleavey, G. F.; Watts, J. K.; Alain, T.; Robert, F.; Kalota, A.; Aishwarya, V.; Pelletier, J.; Gewirtz, A. M.; Sonenberg, N.; Damha, M. J. *Nucleic Acids Res.* 2010, 38, 4547.
- (12) (a) Obika, S. *Chem. Pharm. Bull.* 2004, 52, 1399. (b) Singh, S. K.; Nielsen, P.; Koshkin, A. A.; Wengel, J. *Chem. Commun.* 1998, 455.
- (13) (a) Braasch, D. A.; Jensen, S.; Liu, Y.; Kaur, K.; Arar, K.; White, M. A.; Corey, D. R. *Biochemistry* 2003, 42, 7967. (b) Elmén, J.; Thonberg, H.; Ljungberg, K.; Frieden, M.; Westergaard, M.; Xu, Y.; Wahren, B.; Liang, Z.; Ørum, H.; Koch, T.; Wahlestedt, C. *Nucleic Acids Res.* 2005, 33, 439.
- (14) Terrazas, M.; Ocampo, S. M.; Perales, J. C.; Marquez, V. E.; Eritja, R. *ChemBioChem* 2011, in press doi:10.1002/cbic.201000791.
- (15) (a) Kim, H. S.; Ravi, R. G.; Marquez, V. E.; Maddileti, S.; Wihlborg, A.-K.; Erlinge, D.; Malmsjö, M.; Boyer, J. L.; Harden, T. K.; Jacobson, K. A. *J. Med. Chem.* 2002, 45, 208. (b) Ravi, G.; Lee, K.; Ji, X.; Kim, H. S.; Soltysiak, K. A.; Marquez, V. E.; Jacobson, K. A. *Bioorg. & Med. Chem. Lett.* 2001, 11, 2295.
- (16) For a review, see: Somoza, A. *Chem. Soc. Rev.* 2008, 37, 2668.
- (17) (a) Sproat, B. S. In *Oligonucleotide Synthesis: Methods and Applications*; Herdewijn, P. Ed.; Humana Press: New Jersey, 2005, Vol. 288, p.17-31. (b) Pitsch, S.; Weiss, P. A.; Jenny, L.; Stutz, A.; Wu, X. *Helv. Chim. Acta* 2001, 84, 3773. (c) Shiba, Y.; Masuda, H.; Watanabe, N.; Ego, T.; Takagaki, K.; Ishiyama, K.; Ohgi, T.; Yano, J. *Nucleic Acids Res.* 2007, 35, 3287. (d) Schwartz, M. E.; Breaker, R. R.; Asteriadis, G. T.; deBear, J. S.; Gough, G. R. *Bioorg. Med. Chem. Lett.* 1992, 2, 1019. (e) Harstel, S. A.; Kitchen, D. E.; Scaringe, S. A.; Marsal, W. S. In *Oligonucleotide Synthesis: Methods and Applications*; Herdewijn, P. Ed.; Humana Press: New Jersey, 2005, Vol. 288, p.33-49.
- (18) Umemoto, T.; Wada, T. *Tetrahedron Lett.* 2004, 45, 9529.
- (19) Ohgi, T.; Masutomi, Y.; Ishiyama, K.; Kitagawa, H.; Shiba, Y.; Yano, J. *Org. Lett.* 2005, 7, 3477.

Supporting Information

A direct, efficient method for the preparation of siRNAs containing ribo-like *North* bicyclo[3.1.0]hexane pseudosugars

Montserrat Terrazas,[†] Anna Aviñó,[†] Maqbool A. Siddiqui,[‡] Victor E. Marquez,^{*,‡} and Ramon Eritja^{*,†}

Institute for Research in Biomedicine (IRB Barcelona), Networking Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), and Institute for Advanced Chemistry of Catalonia (IQAC), Spanish Research Council (CSIC), Cluster Building, Baldri i Reixac 10, E-08028 Barcelona, Spain, and Laboratory of Chemical Biology, Center for Cancer Research, National Cancer Institute at Frederick, MD. 21702 USA.

Table of contents

Materials and methods.....	S3
Preparation of 2s	S4
Preparation of 3s	S5
Preparation of 4s	S5
Preparation of 5s	S6
Preparation of 6s	S6
Preparation of 7s	S7
Preparation of 8s	S7
Preparation of 1	S8
Preparation of 2	S8
Preparation of 3	S8
Preparation of 4	S9
Preparation of 5	S9
Solid-phase oligonucleotide synthesis.....	S10
Deprotection and purification of unmodified oligonucleotides sense and guide (6 , wt).....	S10
Deprotection and purification of modified oligonucleotides 7 and 8	S10
General procedure for enzymatic digestion of oligonucleotides.....	S11
UV-monitored thermal denaturation studies.....	S11
RNAi methods.....	S11
Figure S1. ¹ H-NMR spectrum of compound 2s	S13
Figure S2. ¹³ C-NMR spectrum of compound 2s	S13

Figure S3. ^1H -NMR spectrum of compound 3s	S14
Figure S4. ^{13}C -NMR spectrum of compound 3s	S14
Figure S5. ^1H -NMR spectrum of compound 4s	S15
Figure S6. ^{13}C -NMR spectrum of compound 4s	S15
Figure S7. ^1H -NMR spectrum of compound 5s	S16
Figure S8. ^{13}C -NMR spectrum of compound 5s	S16
Figure S9. ^1H -NMR spectrum of compound 6s	S17
Figure S10. ^{13}C -NMR spectrum of compound 6s	S17
Figure S11. ^1H -NMR spectrum of compound 7s	S18
Figure S12. ^{13}C -NMR spectrum of compound 7s	S18
Figure S13. ^1H -NMR spectrum of compound 8s	S19
Figure S14. ^{13}C -NMR spectrum of compound 8s	S19
Figure S15. ^1H -NMR spectrum of compound 1	S20
Figure S16. ^{13}C -NMR spectrum of compound 1	S20
Figure S17. ^1H -NMR spectrum of compound 2	S21
Figure S18. ^{13}C -NMR spectrum of compound 2	S21
Figure S19. ^1H -NMR spectrum of compound 3	S22
Figure S20. ^{13}C -NMR spectrum of compound 3	S22
Figure S21. ^1H -NMR spectrum of compound 4	S23
Figure S22. ^{13}C -NMR spectrum of compound 4	S23
Figure S23. ^1H -NMR spectrum of 5	S24
Figure S24. ^{13}C -NMR spectrum of 5	S24
Figure S25. ^{31}P -NMR spectrum of 5	S25
Figure S26. MALDI-TOF mass spectra of synthesized oligonucleotides.....	S26
Figure S27. Plot of gene-specific RNAi activity for siRNAs formed by unmodified guide strand 6 and modified guide strands 7 and 8 expressed in SH-SY5Y cells.....	S28

Materials and Methods

Common chemicals and solvents in addition to 2-cyanoethyl diisopropylphosphoramidochloridite were purchased from commercial sources and used without further purification. Anhydrous solvents and deuterated solvents (CDCl_3 , CD_3OD and $\text{DMSO-}d_6$) were obtained from reputable sources and used as received.

Reagents for oligonucleotide synthesis including 2'-*O*-TBDMS-protected phosphoramidite monomers of A^{Bz} , C^{Ac} , G^{dmf} and U, the 5'-deblocking solution (3% TCA in CH_2Cl_2), activator solution (0.4M 1*H*-tetrazole in MeCN), Cap A solution (acetic anhydride/pyridine/tetrahydrofuran (1:1:8), Cap B solution [10% *N*-methylimidazole in tetrahydrofuran), oxidizing solution (0.01M iodine in tetrahydrofuran/pyridine/water (7:2:1) or 70% *tert*-butyl hydroperoxide in water, which was diluted to 10% with acetonitrile (synthesis grade) prior to use] and succinyl polystyrene functionalized with 5'-*O*-DMT-2'-deoxythymidine were purchased from commercial sources and used as received.

Nuclease P1 and bacterial alkaline phosphatase were commercially available and used without further purification.


All reactions were carried out under argon atmosphere in oven-dried glassware. Thin-layer chromatography was carried out on aluminium-backed Silica-Gel 60 F₂₅₄ plates. Column chromatography was performed using Silica Gel (60 Å, 230 x 400 mesh). NMR spectra were measured on Varian Mercury-400 or Varian-300 instruments. Chemical shifts are given in parts per million (ppm); *J* values are given in hertz (Hz). All spectra were internally referenced to the appropriate residual undeuterated solvent.

RP-HPLC purifications were performed using a Nucleosil 120-10 C₁₈ column (250x4 mm).

HRMS of compound **5** was performed on a LC/MSD-TOF (Agilent technologies) high resolution mass spectrometer by Servei d'Espectrometria de Masses (Universitat de Barcelona). HRMS of compounds **3** and **4** was performed by (MALDI, positive ion) on a Shimadzu Axima-CFR curved field reflection TOF mass spectrometer using CHCA as the MALDI matrix. APCI MS analyses were conducted on an Agilent LC-MS using flow-injection analysis. Low resolution MS (FAB) for compounds **2s** – **8s** and **1** and **2** was performed on a VG 7070E mass spectrometer and at an accelerating voltage of +8 kV and ionization was effected by a beam of xenon atoms.

MALDI-TOF spectra were performed using a *Perseptive* Voyager DETMRP mass spectrometer, equipped with nitrogen laser at 337 nm using a 3ns pulse. The matrix used contained 2,4,6-trihydroxyacetophenone (THAP, 10 mg/mL in ACN/ water 1:1) and ammonium citrate (50 mg/mL in water).

Synthetic scheme



Preparation of **2s**

A solution of cyclopentenone **1s** (3.92 g, 9.27 mmol) in anhydrous methanol (70 mL) was treated with Cerium(III) chloride heptahydrate (3.20 g, 8.58 mmol). The flask was cooled over ice and treated with portions of sodium borohydride (0.390 g, 10.30 mmol). After 15 minutes, the pH was brought to 4 with acetic acid. Immediately after, water (40 mL) was added and the mixture was extracted with ether (2×100 mL). The combined ether extract was washed with brine (2×60 mL), dried (MgSO_4) and concentrated in vacuo. The crude product was purified by flash chromatography over silica gel using 10 \rightarrow 20% EtOAc in hexanes to give 3.38 g (86.0%) of **2s** as an oil: $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ 7.51-7.61 (m, 4 H), 7.27-7.35 (m, 6 H), 5.76 (m, 1 H), 4.79 (d, $J = 5.5$ Hz, 1

H), 4.67 (td, $J = 6.3, 0.8$ Hz, 1 H), 4.48 (br s, 1 H), 4.31 (dm, $J = 15.2$ Hz, 1 H), 4.21 (dm, $J = 15.2$ Hz, 1 H), 2.60 (br s, 1 H), 1.28 (s, 3 H), 1.26 (s, 3 H), 1.00 (s, 9 H); ^{13}C NMR (100 MHz, CDCl_3) δ 145.2, 135.5, 133.28, 129.7, 129.6, 129.29, 127.7, 112.4, 82.8, 77.9, 73.3, 60.8, 27.6, 26.7, 19.2; FABMS m/z (relative intensity) 425.2 (MH^+ , 17), 463.2 (MK^+ , 100). Anal. Calcd. for $\text{C}_{25}\text{H}_{32}\text{O}_4\text{Si}$: C, 70.72; H, 7.60. Found: C, 70.82; H, 7.60.

Preparation of 3s

An ice-cold solution of **2s** (10.89 g, 25.89 mmol) in anhydrous CH_2Cl_2 (150 mL) was stirred and treated with a solution of Et_2Zn in hexane (1M, 70 mL, 70 mmol) and CH_2I_2 (6 mL, 74.3 mmol). After 15 min, the ice bath was removed while stirring continued for 1.5 h. The reaction mixture was quenched with a saturated aqueous solution of NH_4Cl (100 mL) and extracted with CH_2Cl_2 (2×100 mL). The combined organic layer was washed with saturated aqueous NaHCO_3 (2×100 mL), water (2×100 mL), dried (MgSO_4) and concentrated in vacuo. The crude product was purified by flash chromatography over silica gel using 10 \rightarrow 25% EtOAc in hexanes to give 8.42 g (74.8%) of **3s** as a thick oil: ^1H -NMR (400 MHz, CDCl_3) δ 7.60-7.65 (m, 4 H), 7.34-7.42 (m, 6 H), 5.00 (dd, $J = 7.0, 1.2$ Hz, 1 H), 4.54 (dt, $J = 7.4, 0.8$ Hz, 1 H), 4.45 (br t, $J \approx 6$ Hz, 1 H), 4.06 (d, $J = 11.3$ Hz, 1 H), 3.28 (d, $J = 11.3$ Hz, 1 H), 2.30 (br s, 1 H), 1.60 (m, 1 H), 1.53 (s, 3 H), 1.31 (s, 3 H), 1.08 (irregular t, $J \approx 5$ Hz, 1 H), 1.00 (s, 9 H), 0.53 (m, 1 H); ^{13}C NMR (100 MHz, CDCl_3) δ 135.5, 133.6, 129.7, 127.7, 112.7, 81.1, 79.7, 71.0, 65.3, 35.5, 32.8, 26.9, 26.1, 24.6, 19.2, 10.3 FABMS m/z (relative intensity) 477.2 (MK^+ , 100). Anal. Calcd. for $\text{C}_{26}\text{H}_{34}\text{O}_4\text{Si}$: C, 71.19%; H, 7.81. Found: C, 71.03; H, 8.00.

Preparation of 4s

An ice-cold solution of **3s** (8.33 g, 18.99 mmol) in dry pyridine (100 mL) was treated with $\text{CH}_3\text{SO}_2\text{Cl}$ (3.6 mL, 46.5 mmol). After 10 min, the reaction mixture was warmed to ambient temperature and stirred for 1.5 h. The solvent was removed in vacuo and the crude product was purified by flash chromatography using 20 \rightarrow 33 % EtOAc in hexanes to give 9.80 g (99.8%) of the intermediate mesylate. This intermediate (9.80 g, 19.1 mmol) was immediately dissolved in anhydrous DMF (80 mL) and treated with NaN_3 (12.5 g, 192.2 mmol). The reaction mixture was heated to 100 $^\circ\text{C}$ for 2 h, cooled to ambient temperature, quenched with water (100 mL) and extracted with Et_2O (2×150 mL). The combined ether layer was dried (MgSO_4), concentrated in vacuo and purified by flash chromatography over silica gel using 0 \rightarrow 5% EtOAc in hexanes to give 7.57 g (86.1%) of **4s** as a thick oil: ^1H -NMR (400 MHz, CDCl_3) δ 7.64-7.68 (m, 4 H), 7.35-7.45 (m, 6 H), 5.03 (dd, $J = 7.0, 1.4$ Hz, 1 H), 4.50 (dd, $J = 7.0, 1.4$ Hz, 1 H), 4.03 (d, $J = 10.9$ Hz, 1 H), 3.87 (s, 1 H), 3.42 (d, $J = 10.9$ Hz, 1 H), 1.57 (ddd, $J = 9.3, 4.7, 1.6$ Hz, 1 H), 1.44 (s, 3 H), 1.26 (s, 3 H), 1.06 (s, 9 H), 0.92 (dd, $J = 5.4, 4.3$ Hz, 1 H), 0.75 (ddd, $J = 7.0, 5.4, 1.6$ Hz, 1 H); ^{13}C NMR (100 MHz, CDCl_3) δ 135.6, 133.5, 133.4, 129.7, 127.7, 111.7, 87.6, 80.9, 65.5, 64.6, 37.9, 29.2, 26.8, 25.9, 24.3, 19.3, 11.9; FABMS m/z (relative intensity) 502.2 (MK^+ , 35), 464.2 (MH^+ , 5), 406.2 ($\text{MH}^+ - (\text{CH}_3)_2\text{CO}$). Anal. Calcd. for $\text{C}_{26}\text{H}_{33}\text{N}_3\text{O}_3\text{Si}$: C, 67.35; H, 7.17; N, 9.06. Found: C, 67.21; H, 7.15; N, 9.04.

Preparation of 5s

A stirred, argon-flushed solution of **4s** (2.13 g, 4.59 mmol) in CH₃OH:CH₂Cl₂ (1:1, 40 mL) was treated with 0.2 g of Lindlar's catalyst. The inert gas was evacuated and replaced with a hydrogen-filled balloon. After 18 h, the reaction was filtered over short pad of celite and the solvent was evaporated to dryness. The crude product was purified by flash chromatography over silica gel using 5% EtOAc in hexanes → 100% EtOAc to give 1.76 g (88.0%) of **5s** as a thick oil: ¹H-NMR (400 MHz, CDCl₃) δ 7.65-7.70 (m, 4 H), 7.35-7.45 (m, 6 H), 5.10 (dd, *J* = 7.0, 1.2 Hz, 1 H), 4.35 (dd, *J* = 7.0, 1.5 Hz, 1 H), 4.14 (d, *J* = 10.9 Hz, 1 H), 3.34 (s, 1 H), 3.30 (d, *J* = 10.9 Hz, 1 H), 1.47 (s, 3 H), 1.42 (br s, 2 H), 1.26 (m, 4 H), 1.06 (s, 9 H), 0.91 (irregular t, *J* ≈ 5 Hz, 1 H), 0.60 (ddd, *J* = 8.9, 5.4, 1.6 Hz, 1 H); ¹³C NMR (100 MHz, CDCl₃) δ 135.6, 133.6, 129.7, 127.7, 111.0, 91.2, 80.8, 65.5, 56.7, 37.3, 33.4, 26.9, 26.0, 24.3, 19.3, 12.6; FABMS *m/z* (relative intensity) 467.72 (MK⁺, 10), 438.3 (MH⁺, 20). Anal. Calcd. for C₂₆H₃₅NO₃Si: C, 71.35; H, 8.06; N, 3.20. Found: C, 71.15; H, 8.10; N, 3.17.

Preparation of 6s

A solution of dried AgNCO (4.3 g, 28.6 mmol) in anhydrous benzene (60 mL) was maintained under argon and treated with freshly prepared 3-methoxyacryloyl chloride (1.80 g, 14.93 mmol), which was added drop-wise at ambient temperature. The mixture was then heated to reflux for 1 h and again allowed to reach ambient temperature. After the mixture settled, the supernatant was added via syringe to a stirred, ice-cold solution of **5s** (3.0 g, 6.85 mmol) in anhydrous CH₂Cl₂ (50 mL) that was maintained under an argon atmosphere. The solution was allowed to warm up to ambient temperature and was stirred for 1.5 h. The solvent was then evaporated and the residue was purified by flash chromatography over silica gel using 20% → 50% EtOAc in hexanes to give 3.70 g (95.6%) of the 3-methoxyacryloyl ureido intermediate. This intermediate was dissolved in ethanol (100 mL) and treated with 2N aqueous HCl (10 mL). The solution was then heated to reflux overnight and after cooling to ambient temperature the solvent was removed in vacuo. The residue was triturated with EtOAc (10 mL) and the solid obtained was filtered and washed with hexanes (5 mL). After drying under vacuum, 1.60 g (96.4%) of the free, unprotected uracil nucleoside was obtained: ¹H-NMR (400 MHz, DMSO-*d*₆) δ 7.86 (d, *J* = 8.0 Hz, 1 H), 5.50 (d, *J* = 8.0 Hz, 1 H), 4.98 (d, *J* = 4.3 Hz, 1 H, D₂O exchanged), 4.90 (t, *J* = 5.0 Hz, 1 H, D₂O exchanged), 4.54 (s, 1 H), 4.29-4.38 (m, 2 H; d at 4.30, *J* = 6.6, 1.6 Hz after D₂O), 3.95 (dd, *J* = 11.3, 5.0 Hz, 1 H; d at 3.92, d after D₂O), 3.56 (br t, 1 H), 3.02 (dd, *J* = 11.3, 4.8 Hz, 1 H; d 3.00 after D₂O), 1.09-1.15 (m, 2 H; irregular dd at 1.14 and irregular t at 1.10 after D₂O), 0.49 (m, 1 H; ddd, *J* = 8.5, 4.3, 1.6 Hz after D₂O); FABMS *m/z* (relative intensity) 255.1 (MH⁺, 100), 113 (bH₂⁺, 35). Because this material had a trace impurity, the combined total from this reaction and that of a second reaction (2.43 g, 9.55 mmol) was suspended in anhydrous pyridine (60 mL) and treated with Ac₂O (6.0 mL, 63.5 mmol). After stirring for 1.5 h, the solvent was removed in vacuo, co-evaporated thrice with toluene (3 × 10 mL) and the crude residue was purified by flash chromatography over silica gel using 50% EtOAc in hexanes → 100% EtOAc to give 3.18 g (88.9%) of **6s** as a pure oil: ¹H-NMR (400 MHz, CDCl₃) δ 8.98 (br s, 1 H), 7.35 (d, *J* = 8.2 Hz, 1 H), 5.70 (dd, *J* = 8.2, 2.3 Hz, 1 H), 5.66 (dd, *J* = 7.4, 1.6 Hz, 1 H), 5.16 (dt, *J* = 7.4, 1.6 Hz, 1 H), 4.60 (s, 1 H), 4.40 (d, *J* = 12.1 Hz, 1 H), 3.94 (d, *J* = 12.1 Hz, 1 H), 2.07 (s, 3 H), 2.02 (s, 6 H), 1.46 (dd, *J* = 8.6, 4.3 Hz, 1 H), 1.23 (dd, *J* = 6.2, 4.3 Hz, 1 H), 0.97 (ddd, *J* = 8.6, 6.2, 1.6 Hz, 1 H); ¹³C NMR (100 MHz, CDCl₃) δ 170.6, 170.0, 169.0, 162.8, 150.2, 141.6, 102.8, 76.1, 72.8, 65.2, 64.5, 33.2, 23.8, 20.7, 20.5, 20.4, 12.6; FABMS *m/z* (relative

intensity) 381.1 (MH⁺, 100), 113 (bH₂⁺, 10). Anal. Calcd. for C₁₇H₂₀N₂O₈: C, 53.68; H, 5.30; N, 7.37. Found: C, 53.56; H, 5.25; N, 7.29.

Preparation of 7s

A stirred solution of **6s** (3.17 g, 8.33 mmol), Et₃N (12.10 mL, 86.80 mmol) and triazole (5.90 g, 85.40 mmol) in acetonitrile (150 mL) was cooled over an ice bath. POCl₃ (1.60 mL, 17.40 mmol) was added dropwise and after 15 min the ice bath was removed while stirring continued overnight. The solvent was evaporated and the residue was dissolved in EtOAc (300 mL), washed with water (2 × 100 mL) and dried (MgSO₄). After removing the solvent in vacuo, the crude residue was purified by flash chromatography over silica gel using 50% EtOAc in hexanes → 100% EtOAc to give 2.94 g (81.8%) of the triazole intermediate as a foam. This material was dissolved in 1,4-dioxane (60 mL) and treated with concentrated NH₄OH (15 mL). After stirring at ambient temperature overnight, the solvent was removed in vacuo and the residue was co-evaporated with ethanol (2 × 10 mL) and toluene (2 × 25 mL). The residual material was dissolved in a small amount of methanol and treated in a sealed flask with saturated methanolic ammonia. The mixture was stirred at ambient temperature overnight and after all volatiles were removed the solid obtained was purified by flash chromatography over silica gel using 25% → 50% MeOH in CH₂Cl₂ to give 1.23 g (71.5%) of **7s** as a solid, mp 242-243 °C; [α]_D²⁰ = +13.1 (c 0.50 DMF). The ¹H-NMR spectrum in Figure S11 is in DMSO-*d*₆; a better resolution was obtained after D₂O exchange: ¹H-NMR (400 MHz, DMSO-*d*₆ + D₂O) δ 7.80 (d, *J* = 7.4 Hz, 1 H), 5.67 (d, *J* = 7.4 Hz, 1 H), 4.57 (s, 1 H), 4.28 (d, *J* = 5.8 Hz, 1 H), 3.93 (d, *J* = 11.3 Hz, 1 H), 3.46 (d, *J* = 6.6 Hz, 1 H), 3.02 (d, *J* = 11.3 Hz, 1 H), 1.08 – 1.11 (m, 2 H), 0.48 (br dd, *J* = 10.1, 6.2 Hz, 1 H); ¹³C NMR (100 MHz, DMSO-*d*₆ + D₂O) δ 165.7, 155.9, 142.8, 93.8, 76.6, 70.6, 63.3, 62.5, 37.2, 22.8, 11.1; FABMS *m/z* (relative intensity) 254.1 (MH⁺, 100), 112.1 (bH₂⁺, 40). Anal. Calcd. for C₁₁H₁₅N₃O₄•0.25H₂O: C, 51.26; H, 6.06; N, 16.30. Found: C, 51.50; H, 6.10; N, 16.20.

Preparation of 8s

A stirred suspension of nucleoside **7s** (0.96 g, 3.79 mmol) in anhydrous pyridine (60 mL) was treated with Me₃SiCl (4.80 mL, 37.86 mmol). After 15 min, benzoyl chloride (2.40 mL, 20.65 mmol) was added and kept at ambient temperature for 20 h. After cooling over an ice-bath, the reaction was quenched with water (4 mL) and concentrated NH₄OH (10 mL). After 20 min, the ice bath was removed and stirring continued for 20 min. After removing all volatiles in vacuo the residue was dissolved in water (150 mL) and washed with Et₂O (2 × 75 mL). The aqueous layer was concentrated and lyophilized and then purified twice by flash chromatography over silica gel using 2 → 10% MeOH in CH₂Cl₂ to give 0.686 g (50.8%) of **8s** as a foam. The ¹H-NMR spectrum in Figure S12 is in DMSO-*d*₆; a better resolution was obtained after D₂O exchange: ¹H-NMR (400 MHz, DMSO-*d*₆ + D₂O) δ 8.37 (d, *J* = 7.0 Hz, 1 H), 7.92 (d, *J* = 7.8 Hz, 2 H), 7.44-7.59 (m, 3 H), 7.26 (d, *J* = 7.4 Hz, 1 H), 4.69 (s, 1 H), 4.35 (dd, *J* = 6.6, 1.2 Hz, 1 H), 3.97 (d, *J* = 11.3 Hz, 1 H), 3.60 (m, 1 H), 3.05 (d, *J* = 11.3 Hz, 1 H), 1.23 – 1.26 (irregular dd, 1 H), 1.20 (irregular t, 1 H), 0.55 (ddd, *J* = 8.1, 4.7, 1.6 Hz, 1 H); ¹³C NMR (100 MHz, DMSO-*d*₆ + D₂O) δ 167.7, 162.8, 155.4, 147.0, 133.6, 133.1, 128.8, 96.3, 76.1, 70.4, 64.3, 62.4, 55.3, 37.3, 22.7, 11.3; FABMS *m/z* (relative intensity) 358.1 (MH⁺, 100), 216.1 (bH₂⁺, 65). Anal. Calcd for C₁₈H₁₉N₃O₅•0.40CH₂Cl₂: C, 56.47; H, 5.09; N, 10.73. Found: C, 56.35; H, 5.24; N, 10.95.

Preparation of 1

A suspension of nucleoside **8s** (0.55g, 1.53 mmol) in anhydrous pyridine (20 mL) containing imidazole (0.14 g, 2.05 mmol) was treated with 1,3-dichlorotetraisopropyl disiloxane (TIPS-Cl, 0.90mL, 2.85 mmol). The mixture was stirred at ambient temperature for 1.5 h and then quenched with water (50 mL). Following the extraction with EtOAc (2 × 75 mL), the combined organic layer was dried (MgSO₄), concentrated in vacuo and purified by flash chromatography over silica gel using 50 → 80% EtOAc in hexanes to give 0.765 g (82.80%) of **1** as foam: ¹H-NMR (400 MHz, CDCl₃) δ 8.80 (br s, 1 H), 7.96 (d, *J* = 7.4 Hz, 1 H), 7.85 (v br d, *J* = 5.0 Hz, 2 H), 7.43-7.57 (m, 3 H), 4.85 (s, 1 H), 4.83 (dd, *J* = 6.6, 1.2 Hz, 1 H), 4.05 (d, *J* = 12.5 Hz, 1 H), 3.88 (d, *J* = 6.6 Hz, 1 H), 3.59 (d, *J* = 12.5 Hz, 1 H), 2.78 (s, 1 H), 1.50 (dd, *J* = 3.8, 5.6 Hz, 1 H), 1.30 (ddd, *J* = 1.2, 3.6, 8.9 Hz, 1 H), 0.90- 1.08 (m, 28 H), 0.55 (ddd, *J* = 1.6, 5.6, 8.7Hz, 1 H); ¹³C NMR (100 MHz, CDCl₃) δ 160.8, 145.1, 132.1, 128.0, 126.6, 95.7, 70.6, 63.5, 62.9, 35.2, 24.3, 24.1, 16.4, 16.3, 16.1, 16.0, 12.4, 12.0, 12.1, 11.8, 8.9; FABMS *m/z* (relative intensity) 600.3 (MH⁺, 100), 216.1 (bH₂⁺, 68). Anal. Calcd. for C₃₀H₄₅N₃O₆Si₂: C, 60.07; H, 5.56; N, 7.00. Found: C, 60.01; H, 5.69; N, 6.76.

Preparation of 2

A stirred solution of **1** (0.360 g, 0.60 mmol) in anhydrous THF (25 mL) over molecular sieves (4A, 0.60 g) was treated with a freshly prepared solution of 2-cyanoethyl methylthiomethyl ether (0.48 g, 3.65 mmol). The solution was cooled to – 45 °C and treated with trifluoromethane sulfonic acid (0.30 mL, 3.37 mmol) and N-iodosuccinimide (NIS, 0.70 g, 3.11 mmol). After 30 min, the cooling bath removed and kept for 1.5 h before cooling again to – 45 °C to quench the reaction with Et₃N (0.80 mL). The precipitate was removed by filtration and the filtrate was diluted with EtOAc (200 mL) and successively washed with 1M aqueous Na₂S₂O₄ (1 × 60 mL), saturated aqueous NaHCO₃ (1 × 60 mL) and brine (1 × 60 mL). After removing the solvent the residue was purified by flash chromatography over silica gel using 2 → 5 % MeOH in CH₂Cl₂ to give 0.30 g (73.3%) of **2** as a foam: ¹H-NMR (400 MHz, CDCl₃) δ 8.17 (d, *J* = 7.0 Hz, 1 H), 7.84 (overlapped br d, 2 H), 7.43 – 7.57 (m, 4 H), 4.88 (s, 1 H), 4.79 (m, 2 H), 4.70 (d, *J* = 6.2 Hz, 1 H), 4.32 (d, *J* = 12.5 Hz, 1 H), 4.00 (m, 1 H), 3.81 (d, *J* = 6.2 Hz, 1 H), 3.64 (m, 1 H), 3.29 (d, *J* = 12.5 Hz, 1 H), 2.65 (m, 2 H), 1.64 (dd, *J* = 5.4, 3.5 Hz, 1 H), 1.25 (v br dd, 1 H), 1.03 (m, 28 H), 0.50 (v br ddd, 1 H); ¹³C NMR (100 MHz, CDCl₃) δ 160.8, 144.3, 132.2, 132.0, 128.0, 126.5, 117.21, 95.8, 93.6, 69.6, 61.8, 61.5, 61.4, 33.7, 25.5, 21.8, 17.7, 16.4, 16.3, 16.1, 16.0, 15.9, 12.4, 12.1, 12.0, 11.9, 7.7; FABMS *m/z* (relative intensity) 683.3 (MH⁺, 100), 216.0 (bH₂⁺, 42). Anal. Calcd. for C₃₃H₅₀N₄O₇Si₂•0.50H₂O: C, 59.01; H, 7.42; N, 8.10. Found: C, 59.09; H, 7.42; N, 7.85.

Preparation of 3

A stirred solution of **2** (0.205 g, 0.30 mmol) in MeOH (25 mL) was treated with NH₄F•0.5H₂O (0.412 g, 8.94 mmol) and heated to 55 °C for 2 h. After cooling to ambient temperature, the solvent was removed in vacuo and the residue was purified by flash column chromatography over silica gel using 5 → 10% MeOH in CH₂Cl₂ to give 0.119 g (90.10%) of **3** as a foam: ¹H-NMR (400 MHz, DMSO-*d*₆) δ 11.30 (s, 1 H), 8.56 (d, *J* = 7.4 Hz, 1 H), 8.07 (d, *J* = 7.4 Hz, 2 H), 7.69 (t, *J* = 7.4 Hz, 1 H), 7.57 (t, *J* = 7.8 Hz, 2 H), 7.40 (br d, *J* = 6.6 Hz), 5.13 (t, *J* = 5.0 Hz, 1 H), 4.93 (d, *J* = 6.6 Hz, 1 H), 4.80 (s, 1 H), 4.78 (d, *J* = 7.0 Hz, 1 H), 4.66 (d, *J* = 8.0 Hz, 1 H), 4.57 (irregular t, 1 H), 4.13 (dd, *J* = 11.3, 5.0 Hz, 1 H), 3.79 (t, *J* = 6.2 Hz, 2 H), 3.74 (d, *J* = 6.6 Hz, 1 H), 3.20 (dd, *J* = 11.3, 4.6 Hz, 1 H), 2.84 (t, *J* = 6.2 Hz, 2 H), 1.43 (br dd, *J* ≈ 8, 3 Hz, 1 H), 1.29 (br t, *J* = 4.3 Hz, 1 H), 0.70 (v br ddd, 1 H); ¹³C NMR (100 MHz, CH₃OH-*d*₄) δ 162.8,

146.3, 132.6, 129.0, 128.3, 128.1, 127.7, 118.2, 94.00, 79.5, 70.8, 63.4, 62.5, 62.2, 36.7, 21.6, 17.7, 10.2; FIA-APCI/MS m/z (relative intensity) 441.2 (MH^+ , 100). HRMS (MALDI, positive ion) calcd for $C_{22}H_{24}N_4O_6$: 441.1774 (MH^+), found: 441.1770.

Preparation of 4

A solution of **3** (0.240 g, 0.54 mmol) in pyridine was thrice evaporated (3×5 mL) and finally dissolved in anhydrous pyridine (15 mL). After cooling over an ice bath, the solution was treated with 4,4'-dimethoxytrityl chloride (DMT-Cl, 0.85g; 2.51 mmol) and stirred for 30 min. The ice bath was then removed and after 2 h, EtOAc (200 mL) was added and the organic layer was washed with water (2×100 mL), dried ($MgSO_4$) and concentrated in vacuo. The crude product was purified by flash chromatography over silica gel using 0.4% Et_3N in EtOAc to give a semisolid product that was triturated with hexanes (10 mL), filtered-off and dried in vacuo at 40 °C for 12 h to give 0.266 g (65.8%) of **4** as a foam: 1H -NMR (400 MHz, CH_3OH-d_4) δ 8.75 (d, $J = 7.4$ Hz, 1 H), 7.95 (m, 2 H), 7.20 – 7.63 (m, 13 H), 6.88 (m, 4 H), 4.93 – 5.00 (m, 3 H), 4.05 (m, 1 H), 3.80 – 3.88 (m, 3 H), 3.78 (2 s, 6 H), 2.72 (irregular t, 2 H), 2.60 (d, $J = 10.0$ Hz, 1 H), 1.40 (irregular t, 1 H), 1.28 (m, 1 H), 0.50 (m, 1 H); ^{13}C NMR (100 MHz, CH_3OH-d_4) δ 162.8, 158.8, 158.7, 156.8, 146.1, 144.4, 136.2, 135.6, 133.3, 132.6, 129.8, 129.6, 128.8, 128.0, 127.7, 127.6, 126.6, 118.2, 112.8, 97.7, 93.4, 86.6, 79.0, 71.1, 64.2, 62.9, 60.1, 54.3, 46.8, 34.7, 22.0, 19.4, 17.7, 10.3. FIA-APCI/MS m/z (relative intensity) 765.1 (MNa^+ , 0.3), 303 (DMT^+ , 100). HRMS (MALDI, positive ion) calcd for $C_{43}H_{42}N_4O_8$: 743.3081 (MH^+), found: 743.3080. Anal. Calcd for $C_{43}H_{42}N_4O_8 \cdot 0.50 H_2O$: C, 68.69; H, 5.76; N, 7.45. Found: C, 68.89; H, 5.94; N, 7.12.

Preparation of 5

To a solution of alcohol **4** (229 mg, 0.31 mmol) in CH_2Cl_2 (3.7 mL) at 0 °C, DIPEA (77 μL , 0.44 mmol) and 2-cyanoethyl diisopropylphosphoramidochloridite (198 μL , 0.89 mmol) were added. After 15 min the reaction was allowed to reach room temperature and stirred for 1 h. The reaction was quenched with 5% $NaHCO_3$, extracted with CH_2Cl_2 , dried ($MgSO_4$) and concentrated. The residue was purified by silica column chromatography (hexanes/EtOAc 30:70 + 2% Et_3N) to give 262 mg (90%) of **5** as a mixture of diastereoisomers; 1H NMR (400 MHz, $CDCl_3$) δ 8.70 (d, $J = 7.6$ Hz, 1 H), 8.61 (bs, 1H), 7.90-7.89 (m, 2 H), 7.63-7.21 (m, 13 H), 6.91-6.89 (m, 4 H), 5.12-4.76 (m, 4 H), 4.24-4.09 (m, 3 H), 3.99 (m, 1 H), 3.86 (m, 6 H), 3.73-3.52 (m, 4 H), 2.83-2.49 (m, 5 H), 1.55-1.20 (m, 14 H), 0.55 (m, 1 H). ^{13}C NMR (100 MHz, $CDCl_3$) δ 161.7, 161.6, 158.6, 158.6, 158.5, 144.2, 144.1, 135.9, 135.8, 135.5, 133.0, 132.9, 130.1, 130.0, 129.9, 129.9, 128.9, 128.3, 128.1, 128.0, 127.9, 127.5, 118.5, 118.2, 117.6, 117.5, 113.3, 113.2, 95.0 (d, $J = 4.6$ Hz), 94.7, 86.7, 86.6, 79.1-79.2 (m), 74.0 (d, $J = 14.0$ Hz), 72.7 (d, $J = 10.2$ Hz), 64.0, 63.9, 63.8, 63.7, 63.1, 62.9 (m), 62.5, 58.1, 58.0, 55.2, 55.1, 45.3, 45.2, 43.1 (dd, $J = 2.9$ Hz, $J = 12.6$ Hz), 35.0 (m), 34.8 (m), 25.7, 25.6, 24.8, 24.7, 24.6, 22.9, 22.6, 20.4, 20.3, 20.1, 20.0, 18.7, 18.6, 11.8, 11.7. ^{31}P NMR (110 MHz, $CDCl_3$) δ 150.8, 149.0. HR-ES-MS $[M + H]^+$ Calcd. for $C_{52}H_{60}N_6O_9P$: 943.4159, found: 943.4149.

Solid-phase oligonucleotide synthesis

RNA oligonucleotides were synthesized on the 0.2 μmol scale on an Applied Biosystems 394 synthesizer using 2'-*O*-TBDMS protected phosphoramidites (A^{Bz} , G^{dmf} , C^{Ac} and U). Commercially available succinyl polystyrene functionalized with 5'-*O*-DMT-2'-deoxythymidine was used as the solid support. The following solutions were used: 0.4 M 1*H*-tetrazole in ACN (activation); 3% trichloroacetic acid in DCM (deprotection), acetic anhydride/pyridine/ tetrahydrofuran (1:1:8) (capping A), 10% *N*-methylimidazole in tetrahydrofuran (capping B), 0.01 M iodine in tetrahydrofuran/pyridine/water (7:2:1) (P (III) to P (V) oxidation; for the unmodified sense and guide (**6**, **wt**) oligonucleotides), 10% *tert*-butyl hydroperoxide in acetonitrile/water (96:4) (P (III) to P (V) oxidation; for the modified guide strands **7** and **8**). The coupling time was 15 min. All oligonucleotides were synthesized in DMT-ON mode.

Deprotection and purification of unmodified sense and guide (**6**, **wt**) oligonucleotides

After the solid-phase synthesis, the solid support was transferred to a screw-cap glass vial and incubated at 55 °C for 1 h with 1.5 mL of NH_3 solution (33%) and 0.5 mL of ethanol. The vial was then cooled on ice and the supernatant was transferred into a 2 mL eppendorf tube. The solid support and vial were rinsed with 50% ethanol (2 x 0.25 mL). The combined solutions were evaporated to dryness using an evaporating centrifuge. The residue that was obtained was dissolved in a total volume of 85 μL of 1M TBAF in THF and rocked at room temperature for 12 h. Then, 85 μL of 1M triethylammonium acetate (TEAA) and 330 μL of water were added to the solution. The oligonucleotide was desalted on a NAP-5 column using water as the eluent and evaporated to dryness. The oligonucleotide was purified by HPLC (DMT-ON). Column: Nucleosil 120-10 C_{18} (250x4 mm); 20 min linear gradient from 15% to 80% B and 5 min 80% B, flow rate 3 mL/min; solution A was 5% ACN in 0.1 M aqueous TEAA and B 70% ACN in 0.1 M aqueous TEAA.

The pure fractions were combined and evaporated to dryness. The residue that was obtained was treated with 1 mL of 80% AcOH solution and incubated at room temperature for 30 min. The deprotected oligonucleotide was desalted on a NAP-10 column using water as the eluent. All oligonucleotides were quantified by absorption at 260 nm and confirmed by MALDI mass spectrometry.

Deprotection and purification of modified oligonucleotides **7** and **8**

After the solid-phase synthesis, the solid support was transferred to a screw-cap glass vial and incubated at 35 °C for 24 h with 1.5 mL of NH_3 solution (33%) and 0.5 mL of ethanol. The vial was then cooled on ice and the supernatant was transferred into a 2 mL eppendorf tube. The solid support and vial were rinsed with 50% ethanol (2 x 0.25 mL). The combined solutions were evaporated to dryness using an evaporating centrifuge. The residue that was obtained was dissolved in a mixture formed by 10 μL of *n*-propylamine, 1 μL bis(2-mercaptoethyl) ether and of 100 μL of 1M TBAF in THF and rocked at room temperature for 24 h. Then, 100 μL of 1M triethylammonium acetate (TEAA) and 289 μL of water were added to the solution. The oligonucleotide was

desalted on a NAP-5 column using water as the eluent and evaporated to dryness. The oligonucleotide was purified by HPLC (DMT-ON). Column: Nucleosil 120-10 C₁₈ (250x4 mm); 20 min linear gradient from 15% to 80% B and 5 min 80% B, flow rate 3 mL/min; solution A was 5% ACN in 0.1 M aqueous TEAA and B 70% ACN in 0.1 M aqueous TEAA.

The pure fractions were combined and evaporated to dryness. The residue that was obtained was treated with 1 mL of 80% AcOH solution and incubated at room temperature for 30 min. The deprotected oligonucleotide was desalted on a NAP-10 column using water as the eluent. All oligonucleotides were quantified by absorption at 260 nm and confirmed by MALDI mass spectrometry.

General procedure for enzymatic digestion of oligonucleotides

Each RNA oligomer (0.4 OD units at 260 nm) was incubated with nuclease P1 (0.5 units) at 37 °C for 24 h. Then alkaline phosphatase (1 unit) and buffer (50 mM Tris-HCl, pH 9.3, containing 1 mM MgCl₂, 0.1 mM ZnCl₂ and 1 mM spermidine, final concentrations) were added to give a total volume of 230 µL and the mixture was incubated at 37 °C for a further 24 h. The reaction mixture was analyzed by HPLC.

UV-monitored thermal denaturation studies

Absorbance versus temperature curves of duplexes were measured at 1 µM strand concentration in 15 mM HEPES-KOH (pH 7.4), 1 mM MgCl₂ and 50 mM potassium acetate buffer. Experiments were performed in Teflon-stoppered 1 cm path length quartz cells on a JACSO V-650 spectrophotometer equipped with thermoprogrammer. The samples were heated to 90 °C, allowed to slowly cool to 25 °C, and then warmed during the denaturation experiments at a rate of 1 °C/min to 85 °C, monitoring absorbance 260 nm. The data were analyzed by the denaturation curve processing program, MeltWin v. 3.0. Melting temperatures (T_m) were determined by computerfit of the first derivative of absorbance with respect to $1/T$.

RNAi methods

SH-SY5Y were grown at 37 °C in Dulbecco's modified Eagle medium (DMEM; GIBCO) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin and 100 µg/mL streptomycin. Cells were regularly passaged to maintain exponential growth. Twenty-four hours before transfection at 50–80% confluency, mammalian cells were trypsinized and diluted 1:5 with fresh medium without antibiotics ($1-3 \times 10^5$ cells/mL) and transferred to 24-well plates (500 µL per well). Two luciferase plasmids, *Renilla* luciferase (pRL-TK) and Firefly luciferase (pGL3) from Promega, were used as a reporter and control, respectively. Cotransfection of plasmids and siRNAs was carried out with Lipofectamine 2000 (Life Technologies) as described by the manufacturer for adherent cell lines. Per well, 1.0 µg pGL3-Control, 0.1 µg pRL-TK and 0.03–26 nM siRNA duplex formulated into liposomes, were applied; the final volume was 600 µL per well. The cells were harvested 22 h after transfection, and lysed using passive lysis buffer, 100 µL per well, according to the instructions of the Dual-Luciferase Reporter Assay System (Promega). The luciferase activities of the samples were measured using

a MicroLuma^{Plus} LB 96V (Berthold Technologies) with a delay time of 2 s and an integrate time of 10 s. The following volumes were used: 20 μ L of sample and 30 μ L of each reagent (Luciferase Assay Reagent II and Stop and Glo Reagent). The inhibitory effects generated by siRNAs were expressed as normalized ratios between the activities of the reporter (*Renilla*) luciferase gene and the control (Firefly) luciferase gene.




Figure S1. $^1\text{H-NMR}$ spectrum of compound **2s**




Figure S2. $^{13}\text{C-NMR}$ spectrum of compound **2s**




Figure S3. ¹H-NMR spectrum of compound 3s




Figure S4. ¹³C-NMR spectrum of compound 3s




Figure S5. ¹H-NMR spectrum of compound 4s




Figure S6. ¹³C-NMR spectrum of compound 4s




Figure S7. ¹H-NMR spectrum of compound 5s




Figure S8. ¹³C-NMR spectrum of compound 5s



Figure S9. ¹H-NMR spectrum of compound 6s




Figure S10. ¹³C-NMR spectrum of compound 6s




Figure S11. ¹H-NMR spectrum of compound 7s




Figure S12. ¹³C-NMR spectrum of compound 7s




Figure S13. ¹H-NMR spectrum of compound 8s




Figure S14. ¹³C-NMR spectrum of compound 8s




Figure S15. ¹H-NMR spectrum of compound 1




Figure S16. ¹³C-NMR spectrum of compound 1




Figure S17. ¹H-NMR spectrum of compound 2




Figure S18. ¹³C-NMR spectrum of compound 2




Figure S21. ¹H-NMR spectrum of compound 4




Figure S22. ¹³C-NMR spectrum of compound 4

¹H NMR (CDCl₃, 400 MHz)




Figure S23. ¹H-NMR spectrum of compound 5

^{13}C NMR (CDCl_3 , 100 MHz)




Figure S24. ^{13}C -NMR spectrum of compound 5

^{31}P NMR (CDCl_3 , 110 MHz)




Figure S25. ^{31}P -NMR spectrum of compound 5

Table S1. MALDI-TOF mass spectra of synthesized oligonucleotides


Oligonucleotide	Sequence	MW calcd.	MW found
sense	3'-TTAAAAAGAGGAAGAAGUCUA-5'	6790.0	6787.6
guide, 6 (wt)	5'-UUUUUCUCCUUCUUCAGAU-3'	6423.0	6426.4
guide, 7	5'-UUUUUCU ^{C^N} CUUCUUCAGAU-3'	6431.0	6441.8
guide, 8	5'-UUUUUCU ^{C^N} CUUCU ^{C^N} AGAU-3'	6464.6	6470.8
scr-ss	3'-TTAGGAAAGAAAGAAAGCUAU-5'	6790	6796.5
scr-guide	5'-UCCUUUCUUCUUCGAU-3'	6421.3	6425.4

Figure S26. MALDI-TOF mass spectra of synthesized oligonucleotides

Guide strand **7**

Applied Biosystems Voyager System 2081

Voyager Spec #1=>MC=>BC=>NF0.7[BP = 6441.3, 17247]



Mode of operation: Linear
Extraction mode: Delayed
Polarity: Negative
Acquisition control: Manual

Accelerating voltage: 25000 V
1.7E+4 Grid voltage: 92%
Guide wire 0: 0.04%
Extraction delay time: 400 nsec

Acquisition mass range: 3000 - 9000 Da
Number of laser shots: 200/spectrum
Laser intensity: 3131
Laser Rep Rate: 3.0 Hz
Calibration type: Default
Calibration matrix: 2,5-Dihydroxybenzoic acid
Low mass gate: 500 Da

Digitizer start time: 34.4
Bin size: 2 nsec
Number of data points: 12542
Vertical scale: 200 mV
Vertical offset: 0%
Input bandwidth: 500 MHz

Sample well: 91
Plate ID: PLACA1
Serial number: 2081
Instrument name: Voyager-DE RP
Plate type filename: C:\VOYAGER\100 well plate.plt
Lab name: Servei Espectrometria de Masses

Absolute x-position: 1586.57
Absolute y-position: 1147.95
Relative x-position: -0.933078
Relative y-position: -439.548
Shots in spectrum: 8
Source pressure: 6.77e-007
Mirror pressure: 3.749e-010
TC2 pressure: 0.01818
TIS gate width: 20
TIS flight length: 941.4

Acquired: 16:10:00, May 17, 2010
D:\Voyager\data\masses\Montse T\mt05fr1esquena_0002.dat

Printed: 16:11, May 17, 2010

Guide strand 8




Figure S27. Plot of gene-specific RNAi activity for siRNAs formed by unmodified guide strand **6** and modified guide strands **7** and **8** expressed in

SH-SY5Y cells

